| ObjectiveThe thesis focuses on studying the expression of CD59(complement regulatory protein), Ki67(tumor proliferation marker), P16(tumor suppressor gene) in pancreatic cancer, and their association with the gender, age, clinical stage and degree of tumor differentiation. This will help us to understand the role of these 3 markers in the prevention, diagnosis, treatment and prognosis of pancreatic cancer. Method40 cases of pancreatic carcinoma and 35 cases of surgical resection of normal pancreatic tissue were selected and immunohistochemistry assay was used detect the expression of CD59, Ki67 and P16. Known positive section was selected as the positive control. After that, the data was normalized and results from the two different groups were compared. ResultsFor 40 pancreatic carcinoma in our cohort, the positive expression rate of CD59, Ki67 and P16 was 65%; 77.5% and 42.5%, respectively. For 35 normal pancreatic tissues, the positive expression rate of CD59, Ki67 and P16 was 34.29%, Ki67 51.43% and 88.57%, respectively. The positive expression rate of Ki67 and CD59 in pancreatic cancer group was significantly higher than that in the normal control group. In contrast, the positive expression rate of P16 in the pancreatic cancer group was lower than that in the control group. The expression of CD59, Ki67 and P16 in pancreatic cancer group was significantly higher than that of normal control group( P<0.05).For the intensive expression of CD59 and Ki67, the different groups based on the differentiation degree and clinical stage, lymph node metastasis and distant metastasis of pancreatic cancer were significantly different(P<0.05). In poorly differentiated pancreatic cancer group, the expression of CD59 and Ki67 was found to be higher than that of high and mediate differentiation group. In the clinical stage III and IV group, the expression of CD59 and Ki67 was higher than that of I + II group. In the metastasis group, the expression of CD59 and Ki67 was higher than those without metastasis.The differentiation degree and clinical stage of pancreatic cancer is associated with the expression of P16(P<0.05), but not the distant metastasis group(P=0.05). In high and mediate differentiation group, the expression of P16 was significantly higher lower than that in low differentiation group. In the clinical stage III and IV group, the expression of P16 was higher than that in I + II group.The differentiation of pancreatic cancer, clinical stage, lymph node metastasis, distant metastasis was positively correlated to the expression of CD59 expression(P<0.05), R values were 0.643, 0.564, 0.598, 0.443, respectively. However, there is no association between the age, gender and the expression of CD59(P>0.05). The differentiation degree of the tumor, clinical stage, near lymph node metastasis, distant metastasis was positively correlated to the expression of Ki67 expression(P<0.05). R values were 0.670, 0.652, 0.734, 0.518, respectively. And there was no association between the age and gender and the expression of Ki67(P>0.05). The differentiation of pancreatic cancer, clinical stage, lymph node metastasis, near distant metastasis was negatively related to the expression of Ki67(P<0.05). R values were-0.673,-0.387,-0.551,-0.315, respectively. No correlation was found between the age gender and the expression of P16(P>0.05).In pancreatic cancer group, the expression between CD59 and Ki67 were positively correlated,(P<0.05). However, the expression between CD59 and P16 were negatively correlated(P<0.05), as well as the expression between P16 and Ki67(P<0.05). ConclusionThe high expression of Ki67 and CD59 was associated with the differentiation degree, clinical stage and lymph node metastasis of pancreatic cancer, suggesting that this might be used as one of the biomarker for early diagnosis of pancreatic cancer.The expression of P16 in pancreatic cancer tissue was reduced, and negatively correlated with the degree of differentiation of pancreatic cancer, clinical stage, especially in patients with later stage, suggesting that P16 could be used as a biomarker for the diagnosis of pancreatic cancer in early stage.Our studies suggested that CD59 expression is elevated in pancreatic cancer, and CD59 may be an important molecular target for pancreatic cancer and targeted therapy. |
